



VGX Co-Founder and Chief Medical Officer to Chair Vaccine Discovery and Commercialization Conference

Blue Bell, PA – May 22, 2006 –

VGX Pharmaceuticals announced today that Dr. David B. Weiner, the Company's Co-Founder, Chairman of the Scientific Advisory Board and Dr. C. Jo White, Chief Medical Officer, will co-chair the *Vaccine Discovery and Commercialization Conference* ([Download PDF](#)) from May 23 to 24, 2006 at the Sheraton Philadelphia City Center in Philadelphia, PA. Drs. Weiner and White were selected as chairpersons based on their extensive expertise in discovering and developing novel vaccines for human application.

Dr. Weiner is considered a founder of the area of DNA vaccines, and his laboratory published the first DNA vaccine paper addressing HIV infection. In collaboration with others, Dr. Weiner helped to initiate the first FDA approved clinical trial of a DNA vaccine (HIV env/rev) as a therapy as well as the first prophylactic DNA vaccine trial, and he was a member of the committee that authored the FDA's "points to consider document" establishing the guidelines for clinical evaluation of DNA vaccines. Dr. Weiner's laboratory published the first work reporting that immune responses from HIV DNA vaccine can induce cellular responses in a primate, and can induce some level of protection in a primate. He has over 90 publications in the area of DNA vaccines (270 publications over all).

Dr. White has over 18 years of clinical and product development experience in the biopharmaceutical industry with over 13 years dedicated to clinical developments of several FDA-approved vaccines. She worked at Merck with Dr. Margaret Liu to file the first IND for a DNA influenza vaccine in the early 90s. She filed the initial BLA for the cold adapted influenza vaccine while she was at Aviron. Dr. White has worked on several BLAs and MAAs and has made multiple presentations to the FDA and the ACIP on data from clinical studies of various viral vaccines, resulting not only in licensure of 4 vaccines in the US and Europe and but also universal immunization recommendations by the ACIP for varicella vaccine.

According to the Conference web site (<http://www.marcusevans.com>), Vaccine Discovery and Commercialization Conference is an international conference on examining the science, technology, and business aspects of infectious diseases and how to effectively address this challenge to public health. This conference will strive to provide participants with valuable insight on emerging platforms being explored to design effective next generation vaccines; innovative technologies for vaccine delivery; clinical trials and vaccine production issues; regulatory compliance; and constructive dialogue to ferment strategic outlines for vaccine discovery and commercialization.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases including HIV and hepatitis C virus (HCV) as well as cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, which are currently in Phase II clinical trials. In addition, a Phase I clinical trial will be initiated in 2006 for the Company's lead cancer drug compound, VGX-150 for the treatment of Melanoma. Moreover, VGX Pharmaceuticals' therapeutic platform is designed to advance a strong and continual pipeline of additional drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027 and VGX-750 for inflammatory diseases currently in development. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Vice President

Tel 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com